Rani Therapeutics
Latest round
- Series D
Last raised
- Sep 2017
Total raised
- $90M
Investors
- 10
About Rani Therapeutics
Based in California, US, Rani Therapeutics, LLC was founded in 2012 by founder Mir Imran. Rani Therapeutics' strategy and technology were created at InCube Labs, a multidisciplinary R&D center focused on generating medical advances. In April 2021, Rani Therapeutics filed to become a public company. The company developed a "RaniPill capsule" that can be used to treat diabetes, rheumatoid arthritis, psoriasis, plaque psoriasis, and ankylosing spondylitis, providing patients with an alternative to painful and cumbersome medication injection methods. The company plans to be listed on the Nasdaq under the symbol RANI.
Who invested in Rani Therapeutics
10 investors across 4 rounds
See all investors in Rani Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Rani Therapeutics
Who invested in Rani Therapeutics?
Rani Therapeutics has 10 investors on record across 4 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Rani Therapeutics raised?
Rani Therapeutics has raised 4 venture rounds. Sign up free to see how much each round raised and the total.
When did Rani Therapeutics last raise money?
Rani Therapeutics's most recent round on record is a Series D, in Sep 2017.
What does Rani Therapeutics do?
Based in California, US, Rani Therapeutics, LLC was founded in 2012 by founder Mir Imran.
Where is Rani Therapeutics headquartered?
Rani Therapeutics is headquartered in San Jose, US.
Which VCs invest in companies like Rani Therapeutics?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Rani Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series D
Raising like Rani Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.